Stocks in play: Prometic Life Sciences Inc.
Announced new long-term clinical data from its pivotal Phase 2/3 trial of Ryplazymâą (Plasminogen IV) in patients with congenital plasminogen deficiency. The data demonstrates that in 10 patients treated with RyplazymTM for a total of 48 weeks, there was no recurrence of lesions and no safety or tolerability issues observed related to this longer-term dosing. Prometic Life Sciences Inc.